Clinical Trials Logo

CNS Malignancy clinical trials

View clinical trials related to CNS Malignancy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06150547 Enrolling by invitation - CNS Malignancy Clinical Trials

A Study of Metabolic Agents Following Brain Radiation

Start date: November 14, 2023
Phase:
Study type: Observational

This research is being done to determine if CEST Magnetic Resonance Imaging and F-dopa PET are feasible techniques to detect metabolic differences between tumor and brain.

NCT ID: NCT03055364 Recruiting - CNS Malignancy Clinical Trials

Cognitive Function After Treatment of Primary CNS Malignancy

Start date: May 24, 2017
Phase:
Study type: Observational

In this study, the investigators propose to evaluate cognitive function and determine the feasibility of neurocognitive assessment using a select CogState test battery in patients with primary intracranial malignancies receiving photon- or proton-based cranial irradiation with curative intent. The investigators will use the CogState software to quantify changes in verbal learning, memory, and executive function over the initial months and years following radiation treatment. Cognitive changes and temporal patterns of function will be compared to baseline performance for each patient. Data regarding cognitive function, fatigue, quality of life, and standard patient reported outcomes will be collected to characterize the daily impact of treatment. In addition, observed outcomes will be correlated with dosimetry values, radiation dose volumes, and anatomic dose distribution.

NCT ID: NCT01639911 Completed - Melanoma Clinical Trials

Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors

Start date: August 14, 2013
Phase: Phase 1
Study type: Interventional

This phase I trial using the EffTox design will evaluate activity and safety of alisertib, an Aurora A kinase inhibitor, when given in combination with the selective VEGFR inhibitor pazopanib in patients with advanced, previously treated non-hematologic solid tumors.